Stockreport

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem, Inc.  (VSTM) 
Last verastem, inc. earnings: 10/29 04:17 pm Check Earnings Report
US:NASDAQ Investor Relations: verastem.com
PDF Recurrent low-grade serous ovarian cancer is a rare cancer with no FDA-approved treatmentsCompany seeking accelerated approval and priority review of its NDA submission [Read more]